Robert Orenstein, DO, Mayo Clinic in Arizona, Phoenix, AZ
Download this presentation (494 KB)
United European Gastroenterology Week
October 15-19, 2016, Vienna, Austria
RBX2660, A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection, Is Safe and Effective: Results from a Randomised, Double-Blinded, Placebo-Controlled Trial